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Pulmonary Langerhans cell histiocytosis (LCH) is an uncommon cause of interstitial lung
disease. Corticosteroids and chemotherapeutic agents are frequently used to treat
symptomatic patients but their efficacy is unclear. We describe a 66-year-old with biopsy-
proven pulmonary and systemic LCH, whose pulmonary abnormalities responded
dramatically to treatment with 2-chlorodeoxyadenosine (2-CdA). We propose that, in
selected cases, 2-CdA should be considered in the management of pulmonary LCH.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Treatment options for patients with pulmonary Langerhans
cell histiocytosis (LCH) are limited. Herein, we report a case
of LCH with unusual pulmonary manifestations occurring in a
non-smoker. The radiographic findings in this case illustrated
multiple lung nodules of varying dimensions without upperElsevier Ltd. All rights reserved.
284 5398;
ayo.edu (R. Vassallo).lobe predominance and without cystic change. Both
pulmonary and other manifestation of LCH responded
completely to therapy with systemic 2-chlorodeoxyadeno-
sine (2-CdA).Case report
The patient, a 66-year-old never smoker, initially presented
at another facility because of pain in the shoulder and back.
Physical examination revealed cervical lymphadenopathy
but no other features. A computed tomogram (CT) of the
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discrete pulmonary nodules (ranging in size from a few mm
to 3 cm in diameter—Figure 1). There were no cystic
changes on the chest CT. A deep cervical lymph node
biopsy showed diffuse infiltration by S100 and CD1a
positive Langerhans cells, consistent with a diagnosis of
LCH (Figure 2A). Bronchoscopy and transbronchial biopsies
were performed to evaluate further the lung findings.
Transbronchial biopsy of the 3 cm mass in the right lower
lobe demonstrated LCH (Figure 2B). Histopathology of the
lymph node and bronchoscopic lung biopsy were reviewed by
two expert lung pathologists (M.C.A. and J.L.M.) and
deemed to have diagnostic features of LCH. Pulmonary
function testing and gas exchange were normal. Due to the
history of back pain, a spinal MRI was obtained. This
demonstrated lesions involving multiple vertebral bodies in
the cervical and thoracic regions. He was subsequently
started on systemic chemotherapy with 2-CdA at a dose of
5mg/m2 delivered over a 5-day period once a month for 4
months to complete four cycles. The treatment was well
tolerated with minimal toxicity. Following treatment, the
patient experienced resolution of back pain, and CT of the
chest demonstrated complete resolution of the lung lesions,Figure 1 Chest computed tomogram at the time of presenta-
tion showing a 1 cm nodule in the posterior aspect of the left
upper lobe (upper panel) and a 3 cm mass in the right lower lobe
(lower panel).including the 3 cm mass in the right lower lobe (Figure 3).
Follow-up MRI of the spine demonstrated marked improve-
ment in the abnormal enhancement of multiple vertebral
bodies noted in the MRI obtained at presentation.Discussion
LCH is an uncommon but important cause of lung disease
that may also affect the reticuloendothelial system, bones,
nervous system, skin, and other organs.1 Although compel-
ling evidence implies cigarette smoking as a cause of
isolated pulmonary LCH, the association between smoking
and pulmonary LCH in patients with multi-system LCH is
unclear. For instance, whereas 490% of patients with
isolated forms of pulmonary LCH are either current or
former smokers,1 less than half of adults with multi-system
LCH are smokers.2 The current case report confirms that
smoking is not obligatory for the development of pulmonary
LCH (at least in the context of multi-system disease), as
there was no evidence for either primary or second-hand
tobacco exposure.
The radiographic findings in pulmonary LCH have been
described as characteristic when combinations of cystic and
nodular abnormalities occur with preferential distribution to
the upper and mid-lung zones. Although this pattern
predominates, in certain instances the CT may reveal other
patterns of involvement that suggest alternative diagnoses.3
The current report illustrates an unusual radiographic
presentation of pulmonary LCH with multiple lung nodules
of varying sizes distributed in both lungs, and a 3 cm mass in
the right lower lobe (Figure 1). This radiographic appear-
ance is more consistent with a metastatic malignancy, which
must be carefully ruled out since LCH has been repeatedly
described to predate, co-exist, or occur following the
diagnosis of various malignancies.1,4,5 Although lung nodules
are a characteristic feature of pulmonary LCH, nodules are
typically a centimeter or less in size, and it is distinctly
unusual to see discrete large nodules such as occurred in our
patient.
Treatment of adults with LCH may be challenging. While
smoking cessation is imperative for all patients with
smoking-related pulmonary LCH, treatment decisions in
non-smokers with pulmonary LCH should be based on
determination of the degree of lung impairment together
with careful assessment of disease burden in other organ
systems. The roles of immunosuppressive medications and
chemotherapy in the management of adult pulmonary LCH
in either smokers or non-smokers are unclear. In our patient,
the decision to treat was based primarily on vertebral
involvement which may have led to spinal cord compromise.
Use of 2-CdA was considered appropriate because of
published evidence demonstrating efficacy in adult patients
with refractory LCH,6 and the relatively limited toxicity
associated with 2-CdA therapy in adults with LCH (personal
observations). A trial with high-dose corticosteroids was not
pursued because of limited efficacy and significant adverse
effect profile. The patient had an excellent response to
2-CdA with no evidence of LCH in lungs, spine or lymph
nodes at 18 months of follow-up. Although there are no
definitive recommendations for long-term follow-up, it is
our practice to obtain 6-monthly CT of the chest for the first
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Figure 2 (A) High-power photomicropraph of needle biopsy from cervical lymph node. Immunostaining for the CD1a surface antigen
demonstrates abundant Langerhans cell infiltration (CD1a; 400 ). (B) Intermediate magnification of transbronchial lung biopsy
specimen from the right lower lobe mass showing a dense inflammatory infiltrate including numerous eosinophils. Clusters of
Langerhans cells are present in the inflammatory background. The histologic appearance is characteristic of pulmonary LCH.
M.R. Aerni et al.31812 months after completion of treatment, and subsequently
obtain annual CT for at least an additional 2 years to ensure
a sustained response. Combinations of prednisone and
vinblastine have also been described as effective, particu-
larly in the management of childhood LCH,7 and a
prospective multi-center trial conducted by the Interna-
tional Histiocyte Society (http://www.histio.org) will be
testing the effect of this combination on the lung function of
patients with pulmonary LCH who progress despite smoking
cessation.2-CdA is a purine nucleoside analog that causes lympho-
cyte and monocyte apoptosis (see comprehensive current
review on 2-CdA by Robak et al.8). The efficacy of 2-CdA in
the management of pulmonary LCH in our patient does not
imply that it should have similar efficacy in cigarette
smoking-related pulmonary LCH, that accounts for the
majority of pulmonary LCH encountered by the pulmonary
specialist. It is probable that the pathobiology of smoking-
related pulmonary LCH is distinct from other forms of
pulmonary LCH occurring in non-smokers. This contention is
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Figure 3 The follow-up chest computed tomogram obtained 9
months after presentation and following completion of four
cycles of 2-CdA therapy showed almost complete resolution of
the nodules observed at presentation.
Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions 319partly supported by studies on LCH tissue biopsies obtained
from patients with systemic forms of LCH that demonstrate
clonal expansion,9 whereas lesional cells in the isolated
form of pulmonary LCH are expanded in a polyclonal fashion
suggestive of an antigenically driven response, potentially to
some as yet unknown component in cigarette smoke.10
Ultimately, the role of 2-CdA in the management of
pulmonary LCH remains to be demonstrated by prospective
studies. There are currently no effective interventions that
prolong survival in patients with progressive pulmonary LCH,
other than transplantation in selected cases. With the
response our patient had, we propose that 2-CdA should be
considered as a therapeutic option in patients with
progressive pulmonary LCH.
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